Valiant Co

Valiant Co LT Debt/Equity

The Long-Term Debt to Equity Ratio of Valiant Co (002643.SZ) as of Nov 19, 2026 is 0.18. In the previous year, Long-Term Debt to Equity Ratio was 0.19 — a change of -7.40% (lower).

LT Debt/Equity

0.18

YoY

-7.40%

Last updated:

Long-Term Debt to Equity Ratio of Valiant Co is 2025 0.18 . Long-Term Debt to Equity Ratio of Valiant Co was 2024 0.19 . It decreases by -7.40% lower compared to the previous year.

The Valiant Co LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2018
0.00 CNY
Jan 1, 2019
0.00 CNY
Jan 1, 2020
0.02 CNY
Jan 1, 2021
0.06 CNY
Jan 1, 2022
0.05 CNY
Jan 1, 2023
0.14 CNY
Jan 1, 2024
0.19 CNY
Jan 1, 2025
0.18 CNY
The Valiant Co LT Debt/Equity history
YEARLT Debt/EquityYoY
0.18-7.40%
0.19+34.30%
0.14+161.46%
0.05-8.68%
0.06+180.43%
0.02+2,343.47%
0.00-36.48%
0.00-28.62%
0.00-23.96%
0.00-64.98%
0.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valiant Co Stock analysis

What does Valiant Co do? Valiant Co., Ltd. generates revenue through three core business segments. The Information Materials Industry segment produces and sells display materials and functional materials, targeting customers in the electronics and manufacturing sectors. The Environmental Protection Materials Industry segment develops and manufactures new zeolite environmental protection materials for tail gas purification, serving automotive and industrial clients requiring emission control solutions. The Large Health Industry segment focuses on pharmaceutical production, life sciences, and in vitro diagnostic services, catering to healthcare providers and medical facilities. The company's products include display materials, functional materials, new zeolite environmental protection materials, pharmaceuticals, and in vitro diagnostic services. These offerings are sold across the three industry segments, with the Environmental Protection Materials segment specifically addressing tail gas purification needs. The Large Health Industry segment's in vitro diagnostic services support healthcare operations through specialized medical solutions. Valiant Co., Ltd. serves diverse customer segments including electronics manufacturers, automotive industries, industrial emission control clients, and healthcare providers. The firm's revenue streams are derived from the sale of physical products like display materials and zeolite materials, as well as service-based offerings in diagnostics and pharmaceuticals. The company's business model relies on manufacturing and selling these products across its three operational segments. Valiant Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valiant Co stock

Long-Term Debt to Equity Ratio of Valiant Co is 0.18 in 2025.

Long-Term Debt to Equity Ratio of Valiant Co changed from 0.19 to 0.18, representing a -7.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Valiant Co since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Valiant Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Valiant Co

All Key Metrics — Valiant Co